SG10201900504XA - Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases - Google Patents
Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseasesInfo
- Publication number
- SG10201900504XA SG10201900504XA SG10201900504XA SG10201900504XA SG10201900504XA SG 10201900504X A SG10201900504X A SG 10201900504XA SG 10201900504X A SG10201900504X A SG 10201900504XA SG 10201900504X A SG10201900504X A SG 10201900504XA SG 10201900504X A SG10201900504X A SG 10201900504XA
- Authority
- SG
- Singapore
- Prior art keywords
- eosinophilic
- treatment
- glutarimide derivatives
- pharmaceutical composition
- diseases
- Prior art date
Links
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical class O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000027004 Eosinophilic disease Diseases 0.000 title abstract 2
- 230000002327 eosinophilic effect Effects 0.000 abstract 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 abstract 1
- 206010002199 Anaphylactic shock Diseases 0.000 abstract 1
- 208000028185 Angioedema Diseases 0.000 abstract 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010030216 Oesophagitis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010057271 eosinophilic colitis Diseases 0.000 abstract 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 abstract 1
- 208000006881 esophagitis Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2013150861/15A RU2552929C1 (ru) | 2013-11-14 | 2013-11-14 | Π€Π°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΈΡ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠ°Ρ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΠ΅ Π³Π»ΡΡΠ°ΡΠΈΠΌΠΈΠ΄ΠΎΠ², ΠΈ ΠΈΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»ΡΠ½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201900504XA true SG10201900504XA (en) | 2019-02-27 |
Family
ID=53057723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201900504XA SG10201900504XA (en) | 2013-11-14 | 2014-11-12 | Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases |
Country Status (23)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| SG11201508394UA (en) * | 2013-04-12 | 2015-11-27 | Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmentpr | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | εηε ι«θ₯ε ¬εΈ | θη±ζθο½ο½οΌοΌο½ζεΆεζ²»ηει Έζ§ι£ιηηζΉζ³ |
| KR20160120735A (ko) | 2014-02-28 | 2016-10-18 | 리μ λλ‘ νμλ§μν°μ»¬μ€, μΈν¬. | οΌ©ο½-4ο½ κΈΈνμ μ ν¬μ¬μ μν νΌλΆ κ°μΌμ μΉλ£ λ°©λ² |
| EP4442323A3 (en) | 2016-09-01 | 2025-01-01 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| CN106539792B (zh) * | 2016-11-07 | 2017-08-25 | ηζζ | δΈη§ζ²»ηι«θ‘θηηθ―η© |
| GEP20227402B (en) * | 2017-09-07 | 2022-08-10 | Valenta Intellekt Ltd | Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines |
| RU2712281C1 (ru) | 2018-11-23 | 2020-01-28 | ΠΠ±ΡΠ΅ΡΡΠ²ΠΎ Π‘ ΠΠ³ΡΠ°Π½ΠΈΡΠ΅Π½Π½ΠΎΠΉ ΠΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎΡΡΡΡ "Π₯Π΅ΠΌΠΈΠΌΠΌΡΡΠ½ Π’Π΅ΡΠ°ΠΏΡΡΡΠΈΠΊΡ" | ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ Π³Π»ΡΡΠ°ΡΠΈΠΌΠΈΠ΄Π° Π΄Π»Ρ ΠΏΡΠ΅ΠΎΠ΄ΠΎΠ»Π΅Π½ΠΈΡ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΊ ΡΡΠ΅ΡΠΎΠΈΠ΄Π°ΠΌ ΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ Ρ Π°Π±Π΅ΡΡΠ°Π½ΡΠ½ΡΠΌ ΡΠΈΠ³Π½Π°Π»ΠΈΠ½Π³ΠΎΠΌ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π° Π³Π°ΠΌΠΌΠ° |
| WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| BR112022000581A2 (pt) | 2019-08-05 | 2022-03-03 | Regeneron Pharma | MΓ©todos para tratamento de alergia e intensificação de imunoterapia especΓfica dos alergΓ©nos atravΓ©s da administração de um antagonista de il-4r |
| KR20220044563A (ko) | 2019-08-05 | 2022-04-08 | 리μ λλ‘ νμλ§μν°μ»¬μ€, μΈν¬. | Il-4r κΈΈνμ λ₯Ό ν¬μ¬ν¨μ μν΄ μν νΌ νΌλΆμΌμ μΉλ£νκΈ° μν λ°©λ² |
| BR112022019244A2 (pt) * | 2020-04-07 | 2022-11-08 | Hofseth Biocare Asa | Método para reduzir a função efetora de eosinófilos, artigo de fabricação e kit |
| MA58653B1 (fr) * | 2020-06-26 | 2024-02-29 | Valenta Intellekt Ltd | Utilisation d'un dΓ©rivΓ© de glutarimide pour traiter des maladies liΓ©es Γ l'activitΓ© aberrante d'interleukine-6 |
| WO2023113650A1 (ru) * | 2021-12-15 | 2023-06-22 | ΠΠ»Π°Π΄ΠΈΠΌΠΈΡ ΠΠ²Π³Π΅Π½ΡΠ΅Π²ΠΈΡ ΠΠΠΠΠΠ¬Π‘ΠΠ | Π€Π°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΈΡ 1-[2-(1-ΠΌΠ΅ΡΠΈΠ»ΠΈΠΌΠΈΠ΄Π°Π·ΠΎΠ»-4-ΠΈΠ»)-ΡΡΠΈΠ»]ΠΏΠ΅ΡΠ³ΠΈΠ΄ΡΠΎΠ°Π·ΠΈΠ½-2,6-Π΄ΠΈΠΎΠ½ Π΄Π»Ρ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ Π²Π΅ΡΡ Π½ΠΈΡ Π΄ΡΡ Π°ΡΠ΅Π»ΡΠ½ΡΡ ΠΏΡΡΠ΅ΠΉ |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02196767A (ja) * | 1988-10-11 | 1990-08-03 | Kyowa Hakko Kogyo Co Ltd | γγγγγ΅γ ι Έθͺε°δ½ |
| HU9301856D0 (en) * | 1990-12-24 | 1993-09-28 | Merrell Dow Pharma | Application of glutarimide derivatives for treating depressive and maniacal diseases |
| WO1994024133A1 (en) * | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| AUPO005496A0 (en) | 1996-05-24 | 1996-06-13 | Bresagen Limited | An interleukin-5 antagonist |
| RU2141483C1 (ru) | 1997-07-04 | 1999-11-20 | ΠΠ΅Π±ΠΎΠ»ΡΡΠΈΠ½ ΠΠ»Π°Π΄ΠΈΠΌΠΈΡ ΠΠ²Π³Π΅Π½ΡΠ΅Π²ΠΈΡ | ΠΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΠ΅ ΠΏΠ΅ΠΏΡΠΈΠ΄ΠΎΠ² ΠΈΠ»ΠΈ ΠΈΡ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈ ΠΏΡΠΈΠ΅ΠΌΠ»Π΅ΠΌΡΠ΅ ΡΠΎΠ»ΠΈ, ΡΠΏΠΎΡΠΎΠ± ΠΈΡ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ, ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΈ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΈΡ |
| ATE419007T1 (de) | 2001-11-07 | 2009-01-15 | Cytos Biotechnology Ag | Antigenraster welche il-5, il-13 oder eotaxin prΓ€sentieren, zur behandlung von allergischen, eosinophilen erkrankungen |
| EP1741709A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| WO2007007054A1 (en) | 2005-07-08 | 2007-01-18 | Cancer Research Technology Limited | Phthalamides, succinimides and related compounds and their use as pharmaceuticals |
| SI3072525T1 (en) | 2007-05-14 | 2018-06-29 | Astrazeneca Ab | Procedures for lowering the levels of basophiles |
| RU2378284C2 (ru) * | 2008-02-13 | 2010-01-10 | ΠΠ±ΡΠ΅ΡΡΠ²ΠΎ Π‘ ΠΠ³ΡΠ°Π½ΠΈΡΠ΅Π½Π½ΠΎΠΉ ΠΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎΡΡΡΡ "Π€Π°ΡΠΌΠΈΠ½ΡΠ΅ΡΠΏΡΠ°ΠΉΡΠ΅Π·" | Π‘ΠΏΠΎΡΠΎΠ±Ρ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ n-Π°ΡΠΈΠ»ΡΠ½ΡΡ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΡ Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡ (Π²Π°ΡΠΈΠ°Π½ΡΡ) |
| RU2406727C2 (ru) * | 2008-02-13 | 2010-12-20 | ΠΠ±ΡΠ΅ΡΡΠ²ΠΎ Π‘ ΠΠ³ΡΠ°Π½ΠΈΡΠ΅Π½Π½ΠΎΠΉ ΠΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎΡΡΡΡ "Π€Π°ΡΠΌΠΈΠ½ΡΠ΅ΡΠΏΡΠ°ΠΉΡΠ΅Π·" | Π€Π°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΈΡ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠ°Ρ n-Π°ΡΠΈΠ»ΡΠ½ΡΠ΅ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΠ΅ Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡ, ΠΈ ΠΈΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ , Π°Π½ΡΠΈΠ°Π½Π°ΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΡΡΠ΅Π΄ΡΡΠ² |
| SG11201508394UA (en) | 2013-04-12 | 2015-11-27 | Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmentpr | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
-
2013
- 2013-11-14 RU RU2013150861/15A patent/RU2552929C1/ru active
-
2014
- 2014-11-12 LT LTEP14861410.0T patent/LT3069720T/lt unknown
- 2014-11-12 EA EA201891262A patent/EA032955B3/ru not_active IP Right Cessation
- 2014-11-12 US US15/036,603 patent/US9949962B2/en active Active
- 2014-11-12 MX MX2019006881A patent/MX386887B/es unknown
- 2014-11-12 EP EP18206980.7A patent/EP3466425B1/en active Active
- 2014-11-12 MX MX2016006330A patent/MX365781B/es active IP Right Grant
- 2014-11-12 WO PCT/RU2014/000855 patent/WO2015072893A1/ru active Application Filing
- 2014-11-12 DK DK14861410T patent/DK3069720T3/da active
- 2014-11-12 CN CN201480062492.5A patent/CN105722511B/zh active Active
- 2014-11-12 EP EP14861410.0A patent/EP3069720B1/en active Active
- 2014-11-12 SI SI201431407T patent/SI3069720T1/sl unknown
- 2014-11-12 CN CN201910373584.XA patent/CN110200968A/zh active Pending
- 2014-11-12 KR KR1020207013125A patent/KR102312013B1/ko not_active Expired - Fee Related
- 2014-11-12 EA EA201990529A patent/EA037447B1/ru unknown
- 2014-11-12 PL PL18206980T patent/PL3466425T3/pl unknown
- 2014-11-12 EA EA201690798A patent/EA030961B1/ru not_active IP Right Cessation
- 2014-11-12 ES ES14861410T patent/ES2759530T3/es active Active
- 2014-11-12 JP JP2016530898A patent/JP2016540749A/ja not_active Ceased
- 2014-11-12 KR KR1020167013675A patent/KR102312294B1/ko not_active Expired - Fee Related
- 2014-11-12 AU AU2014349246A patent/AU2014349246C1/en not_active Ceased
- 2014-11-12 PL PL14861410T patent/PL3069720T3/pl unknown
- 2014-11-12 ES ES18206980T patent/ES2836887T3/es active Active
- 2014-11-12 HU HUE14861410A patent/HUE046671T2/hu unknown
- 2014-11-12 BR BR112016010515-0A patent/BR112016010515B1/pt not_active IP Right Cessation
- 2014-11-12 SG SG10201900504XA patent/SG10201900504XA/en unknown
- 2014-11-12 EA EA201891261A patent/EA032940B1/ru not_active IP Right Cessation
- 2014-11-12 CA CA2930231A patent/CA2930231C/en active Active
- 2014-11-12 PT PT148614100T patent/PT3069720T/pt unknown
- 2014-12-11 UA UAA201606370A patent/UA118687C2/uk unknown
-
2016
- 2016-05-01 IL IL245429A patent/IL245429B/en active IP Right Grant
-
2017
- 2017-12-18 US US15/844,703 patent/US10220029B2/en active Active
-
2018
- 2018-10-30 JP JP2018203599A patent/JP6589251B2/ja active Active
- 2018-11-15 AU AU2018264084A patent/AU2018264084C1/en not_active Ceased
-
2019
- 2019-08-21 JP JP2019151258A patent/JP2020002152A/ja not_active Ceased
- 2019-08-21 JP JP2019151253A patent/JP6758677B2/ja not_active Expired - Fee Related
- 2019-11-19 CY CY20191101215T patent/CY1122500T1/el unknown
- 2019-12-11 IL IL271352A patent/IL271352B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201900504XA (en) | Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases | |
| WO2011107608A8 (en) | Heterocyclic amides as rock inhibitors | |
| IN2014DN09352A (enrdf_load_html_response) | ||
| IN2014DN09348A (enrdf_load_html_response) | ||
| GEP201706780B (en) | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| PH12014502041A1 (en) | Heterocyclyl compounds as mek inhibitors | |
| NZ719185A (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| WO2012016186A8 (en) | Macrocyclic kinase inhibitors and uses thereof | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| WO2011158042A3 (en) | Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections | |
| WO2011051490A3 (en) | Heterocyclic derivatives | |
| BR112014004447A2 (pt) | bifenilcarboxamidas como inibidores de quinase rock | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| MX2013004759A (es) | Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl). | |
| MX383551B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida | |
| IN2014DN09347A (enrdf_load_html_response) | ||
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| IN2012DN00239A (enrdf_load_html_response) | ||
| MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). | |
| MX2015007488A (es) | Composicion farmaceutica oftalmologica topica que contiene regorafenib. | |
| WO2014106826A3 (en) | Anthracycline analogue and uses thereof | |
| MX2014001862A (es) | 5-cicloalquil-o 5-heterociclil-nicotinamidas. | |
| MX2014002141A (es) | Carboxamidas de n-(5-cicloalquil - o 5-heterociclil-)-piridin-3-il o. |